secwatch.observer — SEC 8-K summary
======================================

Issuer:     PhenixFIN Corp (PFX)
CIK:        0001490349
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001213900-22-080280
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PhenixFIN Q4 2022: NII $1.9M, NAV $57.49/shr, new $50M credit facility
----------------------------------------------------------------------

- Q4 total investment income $5.1M, net investment income $1.9M.
- NAV $120.8M ($57.49/shr) vs $57.08/shr a year ago; portfolio fair value $193.0M.
- Secured 3-yr $50M credit facility (SOFR+2.90%); will redeem $22.5M 6.125% notes due 2023.
- Repurchased 16.5% of shares outstanding in FY2022; weighted avg yield to maturity 10.85%.
- Net realized loss $10.3M on sale of Path Medical; net unrealized loss $3.7M from market volatility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490349/000121390022080280/0001213900-22-080280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490349/000121390022080280/ea170028-8k_phenixfin.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-080280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer